Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
| Market Cap (Intraday) | 4.57B |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $214.49 |
| 50-Day MA | $242.83 |
| 200-Day MA | $242.12 |
Madrigal Pharmaceuticals Inc Stock, NASDAQ:MDGL
200 Barr Harbor Drive, Suite 200, West Conshohocken, Pennsylvania 19428
United States of America
Phone: +1.267.824.2827
Number of Employees: 376
Description
Madrigal Pharmaceuticals, Inc. engages in the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. The company was founded by Rebecca Taub and Edward Chiang on March 2000 and is headquartered in West Conshohocken, PA.